Pulmonx
Marcee has more than 25 years of successful market development and commercialization experience within the medical device industry. Prior to Pulmonx, Marcee was General Manager at Factory CRO, where she led the development of their US business unit with a focus on market development and commercialization growth. Prior to her time at Factory, Marcee was VP of Marketing and Clinical Affairs for Carbylan Biosurgery, where she was responsible for market needs assessment, clinical education, strategy, and execution. Marcee has held positions of increasing responsibility at Baxter BioSurgery, Cohesion Technologies and Collagen Corporation. Marcee received a BS in Biology and a MS in Immunology from San Jose State University.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1